Xtant Medical Holdings Inc (XTNT) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.106x

Based on the latest financial reports, Xtant Medical Holdings Inc (XTNT) has a cash flow conversion efficiency ratio of 0.106x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($5.38 Million) by net assets ($50.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Xtant Medical Holdings Inc net asset quality index to measure how much of total assets are equity-financed.

Xtant Medical Holdings Inc - Cash Flow Conversion Efficiency Trend (2008–2025)

This chart illustrates how Xtant Medical Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Xtant Medical Holdings Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Xtant Medical Holdings Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Xtant Medical Holdings Inc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Lark Distilling Co. Ltd
AU:LRK
-0.021x
OptimumBank Holdings, Inc.
NYSE MKT:OPHC
0.052x
Pansari Developers Limited
NSE:PANSARI
0.253x
Boustead Heavy Industries
KLSE:8133
-0.181x
Ta Chia Yung Ho Machine Industry Co Ltd
TWO:2221
0.001x
Polaris Office Corp
KQ:041020
0.010x
Formosa Prosonic Industries
KLSE:9172
0.009x
Forian Inc
NASDAQ:FORA
0.108x

Annual Cash Flow Conversion Efficiency for Xtant Medical Holdings Inc (2008–2025)

The table below shows the annual cash flow conversion efficiency of Xtant Medical Holdings Inc from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see Xtant Medical Holdings Inc (XTNT) total market value.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $50.95 Million $12.55 Million 0.246x +188.93%
2024-12-31 $42.96 Million $-11.90 Million -0.277x -49.43%
2023-12-31 $51.35 Million $-9.52 Million -0.185x -18.55%
2022-12-31 $34.17 Million $-5.34 Million -0.156x -1199.56%
2021-12-31 $30.88 Million $439.00K 0.014x +128.22%
2020-12-31 $14.51 Million $-731.00K -0.050x -639.08%
2019-12-31 $-44.20 Million $-413.00K 0.009x +133.74%
2018-12-31 $-43.77 Million $1.21 Million -0.028x -399.22%
2017-12-31 $-58.70 Million $-543.18K 0.009x -99.55%
2016-12-31 $-7.07 Million $-14.41 Million 2.037x +298.69%
2015-12-31 $8.88 Million $-9.10 Million -1.025x -208.83%
2014-12-31 $-7.77 Million $-7.32 Million 0.942x -35.61%
2013-12-31 $-3.84 Million $-5.62 Million 1.463x +157.37%
2012-12-31 $4.23 Million $-10.79 Million -2.550x -90.53%
2011-12-31 $5.50 Million $-7.36 Million -1.338x -109.90%
2010-12-31 $-619.24K $-8.37 Million 13.520x +1825.08%
2009-12-31 $4.68 Million $-3.67 Million -0.784x -123.00%
2008-12-31 $11.34K $38.64K 3.407x --

About Xtant Medical Holdings Inc

NYSE MKT:XTNT USA Medical Devices
Market Cap
$67.23 Million
Market Cap Rank
#20716 Global
#4641 in USA
Share Price
$0.48
Change (1 day)
+2.11%
52-Week Range
$0.45 - $0.92
All Time High
$42.12
About

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validate… Read more